179 related articles for article (PubMed ID: 26486317)
1. Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
Furlotti G; Alisi MA; Cazzolla N; Dragone P; Durando L; Magarò G; Mancini F; Mangano G; Ombrato R; Vitiello M; Armirotti A; Capurro V; Lanfranco M; Ottonello G; Summa M; Reggiani A
J Med Chem; 2015 Nov; 58(22):8920-37. PubMed ID: 26486317
[TBL] [Abstract][Full Text] [Related]
2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Discovery of 1H-Indazole-3-carboxamides as a Novel Structural Class of Human GSK-3 Inhibitors.
Ombrato R; Cazzolla N; Mancini F; Mangano G
J Chem Inf Model; 2015 Dec; 55(12):2540-51. PubMed ID: 26600430
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
6. Identification of small molecules that inhibit GSK-3beta through virtual screening.
Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
[TBL] [Abstract][Full Text] [Related]
8. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.
Kozikowski AP; Gaisina IN; Petukhov PA; Sridhar J; King LT; Blond SY; Duka T; Rusnak M; Sidhu A
ChemMedChem; 2006 Feb; 1(2):256-66. PubMed ID: 16892358
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
Ye Q; Mao W; Zhou Y; Xu L; Li Q; Gao Y; Wang J; Li C; Xu Y; Xu Y; Liao H; Zhang L; Gao J; Li J; Pang T
Bioorg Med Chem; 2015 Mar; 23(5):1179-88. PubMed ID: 25662701
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides as Novel GSK-3β Inhibitors and Anti-Ischemic Agents.
Ye Q; Li Q; Zhou Y; Xu L; Mao W; Gao Y; Li C; Xu Y; Xu Y; Liao H; Zhang L; Gao J; Li J; Pang T
Chem Biol Drug Des; 2015 Oct; 86(4):746-52. PubMed ID: 25711384
[TBL] [Abstract][Full Text] [Related]
11. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.
Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
[TBL] [Abstract][Full Text] [Related]
13. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
Costemale-Lacoste JF; Guilloux JP; Gaillard R
Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
Ye Q; Xu G; Lv D; Cheng Z; Li J; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4302-12. PubMed ID: 19481464
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Saitoh M; Kunitomo J; Kimura E; Hayase Y; Kobayashi H; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GS; Snell GP; Itoh F
Bioorg Med Chem; 2009 Mar; 17(5):2017-29. PubMed ID: 19200745
[TBL] [Abstract][Full Text] [Related]
16. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
[TBL] [Abstract][Full Text] [Related]
18. Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.
Kozikowski AP; Gunosewoyo H; Guo S; Gaisina IN; Walter RL; Ketcherside A; McClung CA; Mesecar AD; Caldarone B
ChemMedChem; 2011 Sep; 6(9):1593-602. PubMed ID: 21732538
[TBL] [Abstract][Full Text] [Related]
19. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
